OBJECTIVE: To report rates of cost-related skipping of medications and other treatments, assess correlates of skipping, examine changes in skipping between 1998 and 2000, and identify factors associated with changes in skipping.
T here are many reasons why people do not adhere to prescribed regimens for medications and other treatments, including costs, side effects, and inconvenience. [1] [2] [3] From a health policy perspective, perhaps the most concerning of these for seniors is cost. If beneficiaries underuse medications and other treatments that might improve their health because of cost, then it is important to understand the magnitude of this problem and to identify potential remedies. The recent passage of the Medicare Modernization Act will reduce out-ofpocket medication costs for some seniors, but for many others, out-of-pocket costs are likely to remain a serious problem. Furthermore, little is known about the impact of other factors such as health status, HMO membership, and physicianpatient relationship quality on cost-related underuse.
Most previous work has focused on cost-related underuse of medications. It is clear that Medicare beneficiaries who do not have prescription drug coverage use fewer medications than those who do have coverage, [4] [5] [6] [7] [8] [9] and to that cost-related underuse of medications is associated with worse health outcomes. 10, 11 Furthermore, recent work shows that cost-related medication underuse is common among adults with chronic illness. 12 However, only 3 papers that we are aware of directly examine the problem of cost-related medication skipping in seniors. 10, 13, 14 Neither of these studies were longitudinal nor were they designed to understand whether physician-patient relationship quality or HMO membership was associated with underuse of medications or other treatments.
To fill in these gaps, we analyzed data from The Study of Choice and Quality in Senior Health Care, a longitudinal study of Medicare beneficiaries aged 65 and older in 13 states. 15 We surveyed beneficiaries in both traditional Medicare and Medicare HMOs in 1998 and 2000. Our analyses had 3 goals: (1) to provide estimates of the rate of cost-related skipping of medications and other treatments in these 13 states, (2) to determine sociodemographic and clinical characteristics associated with skipping, and (3) to determine whether the rate of skipping increased between 1998 and 2000, and if so, why.
METHODS

Study Design and Sampling
The Study of Choice and Quality in Senior Health Care is a longitudinal observational study of Medicare beneficiaries aged 65 and older in states with a history of substantial Medicare HMO enrollment (Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, New Mexico, New York, Oregon, Pennsylvania, Texas, Washington). The sampling strategy is described in detail elsewhere. 15 In these states, we sampled HMOs with risk contracts and at least 3,000 enrollees at the time of sampling. We then sampled beneficiaries from HMOs. Once the HMO sample was drawn, fee-for-service (FFS) beneficiaries were matched to HMO beneficiaries on age, sex, and residential zip code, and randomly sampled in a 1-to-2 ratio (FFS:HMO). Eligibility for sampling included age 65 years, having Medicare Part B, continuous enrollment in either traditional Medicare or an HMO for 1 year. The starting sample had 10,666 Medicare HMO enrollees and 5,332 traditional Medicare enrollees (total N =15,998). All protocols were approved by the Tufts-New England Medical Center Institutional Review Board (IRB).
Data Collection and Survey Response
We used a 5-stage mail and telephone survey protocol. 16 The fall 1998 baseline survey yielded 9,625 responses (response rate 64%), and the 2-year fall 2000 follow-up yielded 6,127 responses (retention rate 71%). Baseline nonresponse and subsequent loss to follow-up were associated with older age, female gender, and minority race/ethnicity (http://www.nemc. org/dccr/PrimaryCareQuality.pdf). Additionally, those lost to follow-up were older, more socioeconomically disadvantaged, and sicker than those retained. Patterns and rates of nonresponse were identical among FFS and HMO enrollees.
Study Variables
To assess cost-related skipping, we asked: ''Do you ever skip medications or treatments because they are too expensive?'' Response options were Yes, often, Yes, occasionally, and No, never, and were dichotomized into yes (often or occasionally) versus no for analyses. We used Andersen's access model 17, 18 to select potential predictors of cost-related skipping. Predisposing factors included age, gender, race (white vs nonwhite), education (less than high school vs high school or greater), and marital status (married vs other). Enabling factors included costs (cost of medications and medical care), ability to pay, use of medical services, and physician-patient relationship quality. Respondents reported monthly out-of-pocket medication costs, with response options: no charge for medications, $1 to $24, $25 to $49, $50 to $99, $100 to $199, and $200 or more. We measured monthly health plan premium costs using the same response categories. We asked patients whether they had ''insurance that covers any of the costs of prescription medication'' (yes vs no). We used income as a proxy for ability to pay, dichotomized at $20,000. For utilization, we measured visits to doctors' offices in the last 6 months and overnight hospitalizations in the last 12 months. We used an indicator for traditional fee-for-service Medicare versus Medicare HMO derived from the CMS database. To measure physician-patient relationship quality, we created a summary score of dimensions of the Primary Care Assessment Survey (PCAS). 19 Four of the 11 PCAS scales (communication, trust, comprehensiveness, and interpersonal care) form a relationship quality factor, 20 which we divided into quartiles. To assess need, we measured the number of medications taken, the number of chronic medical conditions, and health status. For chronic conditions, we used a checklist of 11 conditions (hypertension, angina, congestive heart failure, recent myocardial infarction (MI), heart arrhythmia or valve disorder, stroke, asthma, diabetes, arthritis, any cancer, and depression). 21 We measured physical and mental health status using the Physical (PCS) and Mental Component Score (MCS) of the SF-36. 22 
Analyses
The analytic sample included only survey respondents who reported using 1 or more prescription medications (7, 23 We estimated separate multiple logistic regression models using 1998 and 2000 data. For analyses that examined reasons for changes in cost-related medication skipping over the 2-year study period, and factors associated with these changes, we used patients who responded to surveys in 1998 and 2000, and had no missing data, an observed sample size of 3,043. This approach minimizes the possibility that any differences seen are the result of unmeasured differences between beneficiaries. Because individual beneficiaries' financial and health status can change over time, we adjusted for medication cost, prescription drug coverage, income, membership in an HMO, outpatient visits, inpatient visits, PCS, MCS, disease count, and physician-patient relationship quality.
To determine which variables in our multivariable model were associated with the observed changes in cost-related skipping, we followed a 2-step process. First, we compared the cross-sectional models from 1998 and 2000 to determine whether the odds ratios (ORs) for any of the independent variables had changed significantly. Next, we estimated the impact of these changes on rates of cost-related skipping. We used seemingly unrelated regression, 24 a technique for testing coefficients across different multiple regression models estimated on the same sample, to determine whether the changes seen between 1998 and 2000 in the ORs for variables in our model were statistically significant. To quantify the impact on cost-related skipping of the variables that had changed significantly, we estimated separate multiple linear regression models for 1998 and 2000 using the variables described above. We estimated the impact of a given variable on the rate of costrelated medication skipping by multiplying the regression coefficient by the mean of the variable. We then subtracted the 2000 product from the 1998 product and compared this difference with the change in the rate of cost-related skipping between 1998 and 2000.
To illustrate trends in cost-related skipping, we produced adjusted bar charts of cost-related skipping in 1998 and 2000 by type of Medicare (fee-for-service vs HMO) and out-of-pocket cost group. The percentages in the graphs were adjusted via logistic regression using the same set of variables listed above for the individual 1998 and 2000 multivariable models. Percentages in HMOs were tested with corresponding percentages in FFS within year and out-of-pocket spending category through a joint logistic regression with a full set of system, spending, and year interactions.
We weighted all analyses to reflect the sampling probability. Results should be construed as generalizable to Medicare patients in the 13 study states who have been in their current health plan (either traditional Medicare or an HMO) for 1 or more years. All analyses were carried out using STATA, version 7.0 (College Station, Tex.).
RESULTS
Participant Characteristics
The mean age of beneficiaries represented by our sample in 1998 was 75.3 years (Table 1) . Between 1998 and 2000, beneficiaries reported increases in the number of prescription medications (4.0 to 4.4, P =.0002), out-of-pocket costs (25% spending $50 out-of-pocket per month to 35%, Po.0001), and premiums ($46 to $57, Po.0001). Rates of cost-related skipping increased from 9.5% in 1998 to 13.1% in 2000 (Po.0001).
Bivariate Relationships
Compared with those who reported no cost-related skipping, those who did skip had lower PCS (Table 2, 34.7 vs 40.7, Po.0001) and MCS (46.8 vs 52.5, Po.0001) scores, and were on more prescription medications (4.6 vs 4.0, P =.003). More skipping was reported by low-than high-income beneficiaries (15.2% vs 6.2%), and by those without any versus no prescription drug coverage (16.1% vs 6.8%, Po.0001). Just under 6% of beneficiaries with no out-of-pocket medication costs reported skipping compared with 19.6% costs of $50 or more and 28.2% of those with costs of 4$200 (Po.0001). A similar gradient was seen for the physician-patient relationship quality score.
Multivariable Relationships in 1998 and 2000
Higher monthly medication costs in 1998 were associated with more cost-related skipping of medication and other treatments. Compared with those with no out-of-pocket costs, the ORs for skipping for those spending $50 to $99, $100 to $199, and $200 or more per month were 3.2, 4.0, and 6.1 (all P .0001, Table 3 ). Beneficiaries in the lowest quartile of the physician-patient relationship score had significantly higher odds of skipping (OR 2.2, P =.001) compared with those in the highest quartile. Low-income beneficiaries reported more skipping than high-income beneficiaries (OR 2.2, Po.0001). Beneficiaries lacking prescription medication coverage reported more skipping than those with insurance (OR 1.8, Po.0001). Older beneficiaries skipped less often than younger beneficiaries (OR for each 10-year increment 0.61, Po.0001). Finally, better health was associated with less cost-related skipping for both physical (OR 0.69 for each 10-point increment) and mental health (OR 0.67 for each 10-point increment). The ORs for 5 variables in the model changed significantly between 1998 and 2000: out-of-pocket costs, physician-patient relationship quality, the mental component scale, HMO membership, and high school education. The largest changes were seen in the ORs associated with out-of-pocket medication costs. For those in Medicare HMOs, the OR increased from 1.0 to 1.5 (Po.0001 for the difference). We report in more detail on changes in physician-patient relationship quality elsewhere. 25 
Trends in Cost-related Skipping of Medications and Other Treatments
To understand which of the independent variables that we studied were associated with this increase in cost-related skipping, we examined changes in the aggregate impact of the variables whose ORs changed significantly between 1998 and 2000 (out-of-pocket costs, physician-patient relationship quality, the mental component scale, HMO membership, and high school education). The increase in out-of-pocket costs between 1998 and 2000 (see Table 1 ) combined with the increase in the OR associated with out-of-pocket costs for the same period (see Table 3 ) explained approximately two thirds of the increase in cost-related skipping. The remaining third was explained by the increase in the OR associated with belonging to a Medicare HMO.
Rates of cost-related skipping in fee-for-service and HMOs are compared in 1998 (see Fig. 1 ). In 1998, the rate of cost-related medication skipping was greater in HMOs than fee-for-service in each out-of-pocket cost category, but the only statistically significant difference was seen in the $25 to $49 per month category (Po.001). However, in 2000, there were statistically significant differences in the $1 to $24, $25 to $49, and $50 to $99 categories (all Po.001). The other variables for which the OR changed significantly between 1998 and 2000 (physician-patient relationship quality, MCS, and education) had a negligible impact on changes in skipping rates.
DISCUSSION
There were 3 main findings from this work. First, cost-related skipping of medications and other treatments is relatively common, and increasing. Second, increases in out-of-pocket medication costs and HMO membership explained most of the increase in cost-related skipping between 1998 and 2000. Third, better physician-patient relationship quality is associated with less cost-related skipping.
The mean rates of cost-related skipping of medications and other treatments were 9.5% in 1998 and 13.1% in 2000. These average figures conceal strikingly high rates of skipping in high-risk subgroups. Using our models, the estimated skipping rate for a 65 year old with MCS and PCS of 40, no prescription drug coverage, out-of-pocket costs of 4$50 per month, low income, and a poor physician-patient relationship was 81%. It is difficult to compare our cost-related skipping rates with those of other, contemporaneous studies of patients over 65 because of differences in item content and sampling, but our rates were similar to others. We previously reported data from a 2001 study in which cost-related mediation nonadherence rates varied from 7% to 41% depending on the survey item used and the patient subgroup assessed. 13 Steinman et al. assessed cost-related medication skipping in 1995-1996 and found a rate of 8%, 14 and Mojtabai and Olfson found a rate The OR is the odds of reporting cost-related medication skipping for each 10-point improvement in physical or mental health, and each 10-year increment in age. ‰ P value for the change in the OR from 1998 to 2000, using seemingly unrelated regression method. OR, odds ratio; CI, confidence interval.
of 7% using data from 2000. 10 More importantly, this is the first study we are aware of that assessed cost-related underuse longitudinally, and we document a 38% 2-year increase. Prescription drug costs rose at a rate that far exceeded the Consumer Price Index between 1998 and 2000, [26] [27] [28] [29] which probably explains why the strongest correlate of the increase in cost-related skipping between 1998 and 2000 was rising out-of-pocket drug costs. But, in addition, we observed an increase in odds of skipping for patients with out-of-pocket costs greater than $25. The aggregate impact of increased out-ofpocket costs on cost-related skipping is the product of these two factors. The increase in the OR for out-of-pocket costs may be because many of these patients have fixed incomes. Up to a certain point, they may pay for increases in out-of-pocket drug costs out of savings or other assets. But once a cost threshold is reached, drug costs may compete directly with other necessities like food and utilities. The HMO finding was unexpected, and may be a selection effect. HMO members in this analysis had lower incomes than those in traditional Medicare ($3,072 less in 1998 and $3,876 less in 2000), and probably differed in other ways as well. They may have enrolled in an HMO because of the drug benefit. Changes in HMO prescription drug policies between 1998 and 2000-including fewer offering a pharmacy benefit, drug caps, use of formularies, and increasing copays 30 -may have resulted in increased cost-related skipping for low-income beneficiaries. Coverage arrangements for other treatments (e.g., physical therapy) may have increased in HMOs during these years, but any such changes would likely have been dwarfed in magnitude by changes in drug costs. 30 Further studies of costrelated medication skipping and HMO membership are needed. Recent data from several other studies suggest that physician-patient communication about prescription medication costs is suboptimal. 31 HMOs were less well established. Second, because vulnerable subgroups of seniors, such as minorities and those with low income, are underrepresented here because of higher rates of nonresponse and loss to follow-up, our results may understate rates of cost-related skipping. Third, self-selection of seniors into traditional Medicare versus HMOs may bias system comparisons if important differences between the populations are not captured by the study design and analytic methods. Fourth, self-reported medication skipping of medications and other therapies may underestimate actual skipping. Fifth, we could not separate rates of medication skipping from rates of skipping of other therapies. However, we believe that most of the skipping that we are capturing with the survey item we used is medication related. Over 90% of beneficiaries use prescription medications, whereas only 10% use outpatient therapy services, 33 and out-of-pocket medication costs were a strong correlate of cost-related skipping.
As important as the new prescription drug benefit embodied by the Medicare Modernization Act may be for seniors, we show that cost-related skipping of medications and other treatments is associated with several different factors, including poverty and poor health. If a prescription drug plan requires significant cost sharing, certain vulnerable subgroups will almost certainly continue to experience relatively high cost-related medication skipping rates, particularly low-income seniors whose income or assets may not qualify for any low-income subsidies because their income or assets make them ineligible. 13 An important new finding from this research is that better physician-patient relationships are independently associated with less cost-related skipping. We believe that physicians should initiate discussions about out-of-pocket costs, prescription drug coverage, and cost-related underuse of medications and other therapies with all of their patients. In some cases, it will be possible to substitute high-cost medications with equally effective, lower-cost alternatives.
